binding buffer (Cytiva Europe)
Structured Review
Binding Buffer, supplied by Cytiva Europe, used in various techniques. Bioz Stars score: 95/100, based on 554 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/binding+buffer/Sepharose+6B/pm42140426-111-8-24
Average 95 stars, based on 554 article reviews
Images
Related Articles
Affinity Chromatography:Article Title: Coiled-coil homo-oligomerization and disaggregase Hsp104 act in parallel to stabilize orphan septins Article Snippet: Bovine thrombin (Sigma Aldrich #T7326) was added to the eluted peptide in a 2 U/mg ratio and the solution was dialyzed overnight against buffer ‘1x’ (50 mM Tris pH 8.0, 500 mM NaCl) using a 3 kDa dialysis membrane (Spectrum labs), except for the MBP-fused constructs. .. Solution was loaded to a Pull Down Assay:Article Title: Cucurbitacin B targets PPAT to suppress de novo purine biosynthesis in esophageal squamous cell carcinoma. Article Snippet: Background: The de novo purine biosynthesis (DNPB) pathway is increasingly recognized as a key driver of tumor progression.. Nevertheless, its precise role in regulating esophageal squamous cell carcinoma (ESCC) growth, radiosensitivity, and therapeutic response has not been fully elucidated.. Purpose: This study aimed to determine contribution of phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme of the DNPB pathway, in ESCC progression and potential therapeutic benefit of PPATtargeted intervention. Incubation:Article Title: Cucurbitacin B targets PPAT to suppress de novo purine biosynthesis in esophageal squamous cell carcinoma. Article Snippet: Background: The de novo purine biosynthesis (DNPB) pathway is increasingly recognized as a key driver of tumor progression.. Nevertheless, its precise role in regulating esophageal squamous cell carcinoma (ESCC) growth, radiosensitivity, and therapeutic response has not been fully elucidated.. Purpose: This study aimed to determine contribution of phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme of the DNPB pathway, in ESCC progression and potential therapeutic benefit of PPATtargeted intervention. Negative Control:Article Title: Cucurbitacin B targets PPAT to suppress de novo purine biosynthesis in esophageal squamous cell carcinoma. Article Snippet: Background: The de novo purine biosynthesis (DNPB) pathway is increasingly recognized as a key driver of tumor progression.. Nevertheless, its precise role in regulating esophageal squamous cell carcinoma (ESCC) growth, radiosensitivity, and therapeutic response has not been fully elucidated.. Purpose: This study aimed to determine contribution of phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme of the DNPB pathway, in ESCC progression and potential therapeutic benefit of PPATtargeted intervention. Article Title: The activation of ARF1 is dynamically regulated by its palmitoylation. Article Snippet: .. After taking 50 μl as the ‘input’, the Binding Assay:Article Title: Cucurbitacin B targets PPAT to suppress de novo purine biosynthesis in esophageal squamous cell carcinoma. Article Snippet: Background: The de novo purine biosynthesis (DNPB) pathway is increasingly recognized as a key driver of tumor progression.. Nevertheless, its precise role in regulating esophageal squamous cell carcinoma (ESCC) growth, radiosensitivity, and therapeutic response has not been fully elucidated.. Purpose: This study aimed to determine contribution of phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme of the DNPB pathway, in ESCC progression and potential therapeutic benefit of PPATtargeted intervention. Article Title: The activation of ARF1 is dynamically regulated by its palmitoylation. Article Snippet: .. After taking 50 μl as the ‘input’, the Protease Inhibitor:Article Title: Cucurbitacin B targets PPAT to suppress de novo purine biosynthesis in esophageal squamous cell carcinoma. Article Snippet: Background: The de novo purine biosynthesis (DNPB) pathway is increasingly recognized as a key driver of tumor progression.. Nevertheless, its precise role in regulating esophageal squamous cell carcinoma (ESCC) growth, radiosensitivity, and therapeutic response has not been fully elucidated.. Purpose: This study aimed to determine contribution of phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme of the DNPB pathway, in ESCC progression and potential therapeutic benefit of PPATtargeted intervention. Hemagglutination Assay:Article Title: The activation of ARF1 is dynamically regulated by its palmitoylation. Article Snippet: .. After taking 50 μl as the ‘input’, the Staining:Article Title: A novel strategy for stabilizing the β-catenin destruction complex: Phillygenin targets AXIN1–Dvl interaction to inhibit triple-negative breast cancer Article Snippet: Antibodies against AXIN1, p-β-catenin and HA were from Proteintech (Wuhan, China); antibodies against APC, GSK3β, β-catenin, CK1, Dvl, Transferrin and actin were from Hua Biologics (Hangzhou, China); and antibody against p-PAC was from Affinity Biosciences (Changzhou, China). .. Crystal violet stain was from MedChemExpress (Shanghai, China), Dapi from Yeasen (Shanghai, China), XenoLight D-Luciferin potassium salt from PerkinElmer (Waltham, MA, USA), and |
